

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

**VOLUNTARY ANNOUNCEMENT
LEGEND BIOTECH REGAINS COMPLIANCE
WITH NASDAQ LISTING RULE**

Reference is made to the overseas regulatory announcement of Genscript Biotech Corporation (the “**Company**”) dated 9 January 2023.

Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, announced that Legend Biotech received a notice from the Listing Qualifications Department of the Nasdaq Stock Market (“**Nasdaq**”) on 17 February 2023 indicating that Legend Biotech has regained compliance with Nasdaq Listing Rule 5250(c)(2).

On 6 January 2023, Legend Biotech received a notice of noncompliance from Nasdaq for the delay in filing an interim balance sheet and income sheet for the quarter ended 30 June 2022 on Form 6-K with the SEC. On 17 February 2023, Legend Biotech filed the required Form 6-K to report its unaudited condensed consolidated statements of profit or loss and statements of financial position as of and for the quarter ended 30 June 2022, as required by Nasdaq Listing Rule 5250(c)(2).

For details, please refer to the attached press release. The attachment is the full press release as published on Legend Biotech’s website available at <https://investors.legendbiotech.com/press-releases>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
GenScript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 21 February 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Juan and Dr. Wang Xuehai.

** For identification purposes only*



Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)

Somerset, N.J.—February 21, 2023—Legend Biotech Corporation ("Legend Biotech" or the "Company") (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced that it received notice from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") on February 17, 2023 indicating that the Company has regained compliance with Nasdaq Listing Rules 5250(c)(2).

On January 6, 2023, the Company received a notice of noncompliance from Nasdaq for not filing an interim balance sheet and income statement for the quarter ended June 30, 2022 on Form 6-K with the Securities and Exchange Commission. Pursuant to Listing Rule 5250(c)(2), the Company was required to file such Form 6-K no later than six months following the end of the quarter ended June 30, 2022, or December 31, 2022. This delay in filing such Form 6-K resulted from the Company's planned restatement of its audited financial statements as of and for the years ended December 31, 2021, December 31, 2020 and December 31, 2019 and unaudited interim financial information for the three months ended March 31, 2022, as previously reported by the Company on its Form 6-K dated October 20, 2022.

On February 17, 2023, the Company filed the required Form 6-K to report its unaudited condensed consolidated statements of profit or loss and statements of financial position as of and for the quarter ended June 30, 2022, as required by Nasdaq Listing Rule 5250(c)(2).

###

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on [Twitter](#) and [LinkedIn](#).

Investor Contacts:

Joanne Choi, Senior Manager, Investor Relations, Legend Biotech
joanne.choi@legendbiotech.com

Crystal Chen, Manager, Investor Relations, Legend Biotech
crystal.chen@legendbiotech.com

Press Contact:

Tina Carter, Corporate Communications Lead, Legend Biotech
tina.carter@legendbiotech.com
(908) 331-5025

Source: Legend Biotech

###